188 related articles for article (PubMed ID: 24107192)
1. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
Zhao Y; Yang CY; Wang S
J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
[TBL] [Abstract][Full Text] [Related]
2. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
[TBL] [Abstract][Full Text] [Related]
3. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
[TBL] [Abstract][Full Text] [Related]
6. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
7. New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
Baud MG; Lin-Shiao E; Zengerle M; Tallant C; Ciulli A
J Med Chem; 2016 Feb; 59(4):1492-500. PubMed ID: 26367539
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
9. Bromodomains: a new target class for drug development.
Cochran AG; Conery AR; Sims RJ
Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
[TBL] [Abstract][Full Text] [Related]
10. MCM5 as a target of BET inhibitors in thyroid cancer cells.
Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
[TBL] [Abstract][Full Text] [Related]
11. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Ali I; Lee J; Go A; Choi G; Lee K
Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
[TBL] [Abstract][Full Text] [Related]
13. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
[TBL] [Abstract][Full Text] [Related]
15. Advancements in the Development of non-BET Bromodomain Chemical Probes.
Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of linker length effects on a BET bromodomain probe.
Traquete R; Henderson E; Picaud S; Cal PMSD; Sieglitz F; Rodrigues T; Oliveira R; Filippakopoulos P; Bernardes GJL
Chem Commun (Camb); 2019 Aug; 55(68):10128-10131. PubMed ID: 31386708
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain Drug Discovery - the Past, the Present, and the Future.
Pervaiz M; Mishra P; Günther S
Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
[TBL] [Abstract][Full Text] [Related]
19. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
20. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
